A novel therapeutic approach to depression via supplement with tyrosine hydroxylase

Biochemical and Biophysical Research Communications

Volumn 351, Issue 1, 2006, Pages 140-145

  Fu, Ai Ling ^a,b   Wu, Shao Ping ^b,c   Dong, Zhao Hui ^b   Sun, Man Ji ^b  

^a FUDAN UNIVERSITY   (China)

^b BEIJING INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY   (China)

^c CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

Author keywords

Anti depressant; Depression; Protein therapy; Protein transduction domain; Tyrosine hydroxylase

Indexed keywords

HYBRID PROTEIN; TYROSINE 3 MONOOXYGENASE;

ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DEPRESSION; DRUG BRAIN LEVEL; DRUG EFFECT; DRUG PENETRATION; FORCED SWIMMING TEST; GENETIC TRANSDUCTION; LOCOMOTION; MALE; MESENCEPHALON; MOUSE; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; TAIL FLICK TEST;

ANIMALS; ANTIDEPRESSIVE AGENTS; BEHAVIOR, ANIMAL; BRAIN; DEPRESSION; MALE; MICE; MICE, INBRED ICR; NEURONS; TREATMENT OUTCOME; TYROSINE 3-MONOOXYGENASE;

EID: 33750345187     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2006.10.013     Document Type: Article

References (29)

1. Ressler K.J., and Nemeroff C.B. Role of norepinephrine in the pathophysiology and treatment of mood disorders. Biol. Psychiatry 46 (1999) 1219-1233
2. Tremblay P., and Blier P. Catecholaminergic strategies for the treatment of major depression. Curr. Drug Targets 7 (2006) 149-158
3. Schildkraut J.J., and Kety S.S. Biogenic amines and emotion. Science 156 (1967) 21-37
4. Millan M.J. Multi-target strategies for the improved treatment of depressive states: conceptual foundations and neuronal substrates, drug discovery and therapeutic application. Pharmacol. Ther. 110 (2006) 135-370
5. Cryan J.F., O'Leary O.F., Jin S.H., Friedland J.C., Ouyang M., Hirsch B.R., Page M.E., Dalvi A., Thomas S.A., and Lucki I. Norepinephrine-deficient mice lack responses to antidepressant drugs, including selective serotonin reuptake inhibitors. Proc. Natl. Acad. Sci. USA 101 (2004) 8186-8191
6. Li H.F., Gray A.J., Hirata-Fukae C., Loftus L.T., Stoica B.A., Futami J., Yamada H., Aisen P.S., and Matsuoka Y. In vivo protein transduction to the CNS. Neurosciences 139 (2006) 1061-1067
7. Noguchi H., and Matsumoto S. Protein transduction technology: a novel therapeutic perspective. Acta Med. Okayama 60 (2006) 1-11
8. Wu S.P., Fu A.L., Wang Y.X., Yu L.P., Jia P.Y., Li Q., Jin G.Z., and Sun M.J. A novel therapeutic approach to 6-OHDA-induced Parkinson's disease in rats via supplementation of PTD-conjugayed tyrosine hydroxylase. Biochem. Biophys. Res. Commun. 346 (2006) 1-6
9. Lowry O.H., Rosebrough N.J., Farr A.L., and Randall R.J. Protein measurement with the folin phenol reagent. J. Biol. Chem. 193 (1951) 265-275
10. Porsolt R.D., Anton G., Blavet N., and Jalfre M. Behavioural despair in rats: a new model sensitive to antidepressant treatments. Eur. J. Pharmacol. 47 (1978) 379-391
11. Steru L., Chermat R., Thierry B., and Simon P. The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology 85 (1985) 367-370
12. Miura H., Qiao H., Kitagami T., Ohta T., and Ozaki N. Fluvoxamine, a selective serotonin reuptake inhibitor, suppresses tetrahydrobiopterin levels and dopamine as well as serotonin turnover in the mesoprefrontal system of mice. Psychopharmacology 177 (2005) 307-314
13. Nestler E.J., and Carlezon Jr. W.A. The Mesolimbic dopamine reward circuit in depression. Biol. Psychiatry 59 (2006) 151-1159
14. Porsolt R.D., Bertine A., and Jalfre M. Behavioral despair test in mice: a primary screening test for antidepressants. Arch. Int. Pharmacodyn. 229 (1977) 327-336
15. Yin W., Cao G., Johnnides M.J., Signore A.P., Luo Y., Hickey R.W., and Chen J. TAT-mediated delivery of Bcl-xL protein is neuroprotective against neonatal hypoxic-ischemic brain injury via inhibition of caspases and AIF. Neurobiol. Dis. 21 (2006) 358-371
16. Yan B., Wang D.Y., Xing D.M., Ding Y., Wang R.F., Lei F., and Du L.J. The antidepressant effect of ethanol extract of radix puerariae in mice exposed to cerebral ischemia-reperfusion. Pharmacol. Biochem. Behav. 78 (2004) 319-325
17. Daubner S.C., Lohse D.L., and Fitzpatrick P.F. Expression and characterization of catalytic and regulatory domains of rat tyrosine hydroxylase. Protein Sci. 2 (1993) 1452-1460
18. Abate C., Smith J.A., and Joh T.H. Characterization of the catalytic domain of bovine adrenal tyrosine hydroxylase. Biochem. Biophys. Res. Commun. 151 (1988) 1446-1453
19. Fujisawa H., and Okuno S. Regulatory mechanism of tyrosine hydroxylase activity. Biochem. Biophys. Res. Commun. 336 (2005) 1-6
20. Brady L.S., Lynn A.B., Glowa J.R., Le D.Q., and Herkenham M. Repeated electroconvulsive shock produces long-lasting increases in messenger RNA expression of corticotropin-releasing hormone and tyrosine hydroxylase in rat brain. Therapeutic implications. J. Clin. Invest. 94 (1994) 1263-1268
21. Thony B., Auerbach G., and Blau N. Tetrahydrobiopterin biosynthesis, regeneration and function. Biochem. J. 347 Pt 1 (2000) 1-16
22. Birkmayer J.G.D., and Birkmayer W. The coenzyme nicotinamide adenine dinucleotide (NADH) as biological antidepressive agent experience with 205 patients. New Trend Clin. Neuropharmacol. 314 (1991) 75-86
23. Sakurada K., Ohshima-Sakurada M., Palmer T.D., and Gage F.H. Nurr1, an orphan nuclear receptor, is a transcriptional activator of endogenous tyrosine hydroxylase in neural progenitor cells derived from the adult brain. Development 126 (1999) 4017-4026
24. Zhu M.Y., Klimek V., Dilley G.E., Haycock J.W., Stockmeier C., Overholser J.C., Meltzer H.Y., and Ordway G.A. Elevated levels of tyrosine hydroxylase in the locus coeruleus in major depression. Biol. Psychiatry 46 (1999) 1275-1286
25. Baumann B., Danos P., Diekmann S., Krell D., Bielau H., Geretsegger C., Wurthmann C., Bernstein H.G., and Bogerts B. Tyrosine hydroxylase immunoreactivity in the locus coeruleus is reduced in depressed non-suicidal patients but normal in depressed suicide patients. Eur. Arch. Psychiatry Clin. Neurosci. 249 (1999) 212-219
26. Biegon A., and Fieldust S. Reduced tyrosine hydroxylase immunoreactivity in locus coeruleus of suicide victims. Synapse 10 (1992) 79-82
27. Ordway G.A., Smith K.S., and Haycock J.W. Elevated tyrosine hydroxylase in the locus coeruleus of suicide victims. J. Neurochem. 62 (1994) 680-685
28. Nestler E.J., McMahon A., L Sabban E., Tallman J.F., and Duman R.S. Chronic antidepressant administration decreases the expression of tyrosine hydroxylase in the rat locus coeruleus. Proc. Natl. Acad. Sci. USA 87 (1990) 7522-7526
29. Komori K., Kunimi Y., Yamaoka K., Ito T., Kasahara Y., and Nagatsu I. Semiquantitative analysis of immunoreactivities of tyrosine hydroxylase and aromatic L-amino acid decarboxylase in the locus coeruleus of desipramine-treated mice. Neurosci. Lett. 147 (1992) 197-200